购物车0
产品总数：60952
| 中文名称 |
Combretastatin A4
|
|---|---|
| 中文别名 |
康普瑞汀;康布瑞汀;康普立停 A4;(Z)-2-甲氧基-5- (3,4,5-三甲氧基苯乙烯基)苯酚;(Z)-2-甲氧基-5-(3,4,5-三甲氧基苯乙烯)苯酚;(Z)-3, 4, 5,4’,-四甲氧基-3’-羟基二苯乙烯;(Z)-3,4,5,4',-四甲氧基-3'-羟基二苯乙烯;Combretastatin A4 康普立停 A4;Combretastatin A4 抑制剂;康普瑞丁;康普瑞丁A4;康普瑞汀 A4;康普瑞汀 康普瑞丁;康普瑞汀(康布瑞汀);考布他汀A4;3'-羟基-3,4,4',5-四甲氧基-顺-均二苯乙烯;康普瑞汀(CA-4);3'-羟基-3,4,4',5-四甲氧基-顺-芪;考布他丁A4;康普瑞汀标准品;(Z)-2-甲氧基-5-(3,4,5-三甲氧基苯乙烯基)苯酚;康普瑞汀 1G;康普瑞汀A4
|
| 英文名称 |
Combretastatin A4
|
| 英文别名 |
COMBRETASTATIN A-4;(Z)-2-Methoxy-5-(3,4,5-Trimethoxystyryl)Phenol;(Z)-2-Methoxy-5-[2-(3,4,5-trimethoxyphenyl)ethenyl]phenol,3,4,5-Trimethoxy-3hydroxy-4methoxy-(Z)-stilbene,CS-A4;Combrestatin A4( 2-Methoxy-5-[2-(3,4,5-trimethoxy-phenyl)-vinyl]-phenol );CA-4;Combretastatin A4;2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]Phenol;Combrestatin A4;CRC 87-09;2-methoxy-5-[(Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenol;3'-Hydroxy-3,4,4',5-tetramethoxy-cis-stilbene;1-(3,4,5-Trimethoxyphenyl)-2-(3′-hydroxy-4′-methoxyphenyl) ethane 3,4,5-trimethoxy-3′-hydroxy-4′-methoxystilbene;CA4;CS-A4;CoMbretastatin A;(Z)-CombretastatinA4;CA-4, Combretastatin A-4;combretastatin A-4 (CA-4);Combretastatin A4 (CRC 87-09);(Z)-5-(3,4,5-trimethoxystyryl)-2-methoxyphenol;Combretastatin-A4;16U6OP69RQ;HVXBOLULGPECHP-WAYWQWQTSA-N;3,4,5-Trimethoxy-3'-hydroxy-4'-methoxystilbene;2-Methoxy-5-[(Z)-2-(3,4,5-trimethoxy-phenyl)-vinyl]-phenol;1
|
| Cas No. |
117048-59-6
|
| 分子式 |
C18H20O5
|
| 分子量 |
316.35
|
| 包装储存 |
Powder； -20°C； 3 years; 4°C； 2 years；
|
| 生物活性 |
Combretastatin A4 is a microtubule-targeting agent that binds β-tubulin with Kd of 0.4 μM.
|
|---|---|
| 性状 |
Solid
|
| IC50 & Target[1][2] |
Kd: 0.4 μM (β-tubulin)
|
| 体外研究(In Vitro) |
Combretastatin A4 phosphate (≥ 50 μM) significantly increases the percentage of annexin-V-binding cells and significantly decreases forward scatter. Combretastatin A4 phosphate does not appreciably increase hemolysis. Hundred μM Combretastatin A4 phosphate significantly increases Fluo3-fluorescence. The effect of Combretastatin A4 phosphate (100 μM) on annexin-V-binding is significantly blunted, but not abolished, by removal of extracellular Ca. Combretastatin A4 phosphate (≥ 50 μM) significantly decreases GSH abundance and ATP levels but does not significantly increase ROS or ceramide. Polymersomes co-encapsulating doxorubicin-combretastatin-A4 phosphate (1:10) shows strong synergistic cytotoxicity against human nasopharyngeal epidermal carcinoma (KB) cells. Pretreatment with Combretastatin A4 phosphate does not influence the amount of VM in 3-D culture as well as the express
|
| 体内研究(In Vivo) |
DBP and MBP at 30 minutes after administration are higher in rats treated with Combretastatin A4 disodium phosphate 120 mg/10 mL/kg. The toxicokinetic parameters of Combretastatin A4 phosphate and Combretastatin A4 in rats treated with Combretastatin A4 disodium phosphate 120 mg/10 mL/kg are indicated, and the values of Cmax, T1/2, and AUC0-inf for Combretastatin A4 are 156±13 μM, 5.87±1.69 h, and 89.4±10.1 h·μM, respectively. In vivo, W256 tumors show marked intratumoral hypoxia after Combretastatin A4 phosphate treatment, accompanied by increased VM formation. Combretastatin A4 phosphate exhibits only a delay in tumor growth within 2 days but rapid tumor regrowth afterward. VM density is positively related to tumor volume and tumor weight at day 8. Combretastatin A4 phosphate causes hypoxia which induces VM formation in W256 tumors through HIF-1α/EphA2/PI3K/matrix metallopro
|
| 运输条件 |
Room temperature or refrigerated transport.
|
| 储存方式 |
Powder； -20°C； 3 years; 4°C； 2 years；
|
| ClinicalTrial |
|
| 结构分类 |
PhenolsMonopheno
|
| 来源 |
Plantsother fami
|
| 溶解度数据 |
体外研究:DMSO : 100 mg/mL(316.11 mM;Need ultrasonic)配制储存液
|
|---|
1：一般建议：溶解度为Medlife测试数据，可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异，仅做参考，具体以实验方案为准。
2：储存条件：粉末-20°C一般情况可以保存3年，溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异，请细致阅读产品信息，并辅助参考相关文献描述。
Copyright © 2025 陌孚医药 All rights reserved 未经授权禁止拷贝本站所有资料，如有违反，将追究法律责任。
沪ICP备2023012080号 | 
沪公网安备31011402010657号
扫码关注公众号
产品使用指南
